Shenzhen Kangtai Biological Products (300601.SZ): Recombinant Hepatitis B Vaccine (Brewer's Yeast) (60g) added a new clinical trial approval for the new target population project.

18:09 17/12/2025

Kangtai Biotech (300601.SZ) announced that the company's developed recombination hepatitis B vaccine (brewer's yeast) (60g) has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration today for the new target population project. This product meets the relevant requirements for drug registration and is approved to conduct clinical trials for the prevention of HBsAg reactivation in the functional (clinical) cure population of chronic hepatitis B.

Shenzhen Kangtai Biological Products (300601.SZ) announced that the company's developed recombinant hepatitis B vaccine (brewer's yeast) (60g) has been approved by the National Medical Products Administration for a new target population project. The drug has received the "Drug Clinical Trial Approval Notice" and meets the relevant requirements for drug registration. It has been approved to conduct clinical trials for the prevention of HBsAg reactivation in chronic hepatitis B functional (clinical) cure population.

LEVER STYLE (01346) plans to acquire AAG Australia and America assets for $13 million.

ORG Technology (002701.SZ) subsidiary plans to sell 80% of the shares in Belgium Beindu to Rexam Limited.

On December 17th, DMALL (02586) spent 1.902 million Hong Kong dollars to repurchase 269,100 shares.

LEVER STYLE (01346) plans to acquire AAG Australia and America assets for $13 million.

ORG Technology (002701.SZ) subsidiary plans to sell 80% of the shares in Belgium Beindu to Rexam Limited.

On December 17th, DMALL (02586) spent 1.902 million Hong Kong dollars to repurchase 269,100 shares.